Amicus Therapeutics plans to price public offering of common shares

Company intends to sell stock through Leerink Swann, Cowen and Co.

By Devika Patel

Knoxville, Tenn., March 1 - Amicus Therapeutics, Inc. will price a public offering of stock with a 15% greenshoe, according to a prospectus supplement filed Thursday with the Securities and Exchange Commission.

Leerink Swann LLC and Cowen and Co., LLC are the joint bookrunning managers.

Proceeds will be used to advance drug programs, take advantage of potential business development opportunities and for other general corporate purposes.

Amicus is a Cranbury, N.J., biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.